| Autor: |
Florencio AC; Department of Medicine, School of Medicine, University of São Paulo, São Paulo, SP, Brazil., de Almeida RS; Department of Medicine, School of Medicine, University of São Paulo, São Paulo, SP, Brazil., Arantes-Costa FM; Department of Medicine, School of Medicine, University of São Paulo, São Paulo, SP, Brazil., Saraiva-Romanholo BM; Department of Medicine, School of Medicine, University of São Paulo, São Paulo, SP, Brazil., Duran AF; Natural and Human Sciences Center, Federal University of ABC, Santo André, SP, Brazil., Sasaki SD; Natural and Human Sciences Center, Federal University of ABC, Santo André, SP, Brazil., Martins MA; Department of Medicine, School of Medicine, University of São Paulo, São Paulo, SP, Brazil., Lopes FDTQS; Department of Medicine, School of Medicine, University of São Paulo, São Paulo, SP, Brazil., Tibério IFLC; Department of Medicine, School of Medicine, University of São Paulo, São Paulo, SP, Brazil., Leick EA; Department of Medicine, School of Medicine, University of São Paulo, São Paulo, SP, Brazil. leick51@yahoo.com.br. |
| Abstrakt: |
To evaluate whether a recombinant serine protease inhibitor (rBmTI-A) modulates inflammation in an experimental model of chronic allergic lung inflammation. Balb/c mice were divided into four groups: SAL (saline), OVA (sensitized with ovalbumin), SAL + rBmTI-A (control treated with rBmTI-A) and OVA + rBmTI-A (sensitized with ovalbumin and treated with rBmTI-A). The animals received an intraperitoneal injection of saline or ovalbumin, according to the group. The groups received inhalation with saline or ovalbumin and were treated with rBmTI-A or saline by nasal instillation. After 29 days, we evaluated the respiratory mechanics; bronchoalveolar lavage fluid (BALF); cytokines; MMP-9, TIMP-1; eosinophils; collagen and elastic fibre expression in the airways; and the trypsin-like, MMP-1, and MMP-9 lung tissue proteolytic activity. Treatment with rBmTI-A reduced the trypsin-like proteolytic activity, the elastance and resistance maximum response, the polymorphonuclear cells, IL-5, IL-10, IL-13 and IL-17A in the BALF, the expression of IL-5, IL-13, IL-17, CD4+, MMP-9, TIMP-1, eosinophils, collagen and elastic fibres in the airways of the OVA + rBmTI-A group compared to the OVA group (p < 0.05). rBmTI-A attenuated bronchial hyperresponsiveness, inflammation and remodelling in this experimental model of chronic allergic pulmonary inflammation. This inhibitor may serve as a potential therapeutic tool for asthma treatment. |
